Our Purpose

As a non-profit biotech, our mission makes us unique: IDRI targets diseases that largely affect individuals living in economically challenged countries that have difficulty meeting the public health burden of disease.

Our purpose is finding effective tools to prevent, diagnose and cure these infectious diseases.

 

IDRI Researchers Participate in International Leprosy Congress 
IDRI  Newsletter
Spring Issue 2008 pdf




    

IDRI and Immune Design Corp. 
Enter License Agreement
on GLA Vaccine Adjuvant
 
SEATTLE, Nov. 20, 2008 -- 
IDRI and Immune Design Corp. announced today that they have entered into an agreement pursuant to which Immune Design Corp. is granted a worldwide exclusive license for the research, development, and commercialization of IDRI’s Glycopyranosyl Lipid Adjuvant (GLA) technology for products targeting a number of indications. 

Read entire press release